{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T06:59:42Z","timestamp":1791874782058,"version":"4.3.4"},"reference-count":96,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.ctrv.2024.102772","type":"journal-article","created":{"date-parts":[[2024,5,26]],"date-time":"2024-05-26T14:08:05Z","timestamp":1716732485000},"page":"102772","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["A systematic review of antibody-drug conjugates and bispecific antibodies in head and neck squamous cell carcinoma and nasopharyngeal carcinoma: Charting the course of future therapies"],"prefix":"10.1016","volume":"128","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7695-675X","authenticated-orcid":false,"given":"Pablo","family":"Jim\u00e9nez-Labaig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Rullan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Hernando-Calvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Llop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shreerang","family":"Bhide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"O\u2019Leary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Bra\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin J.","family":"Harrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ctrv.2024.102772_b0005","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102772_b0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41572-020-00224-3","article-title":"Head and neck squamous cell carcinoma","volume":"6","author":"Johnson","year":"2020","journal-title":"Nat Rev Dis Primer"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102772_b0015","doi-asserted-by":"crossref","first-page":"e49968","DOI":"10.2196\/49968","article-title":"Nasopharyngeal Cancer Incidence and Mortality in 185 Countries in 2020 and the Projected Burden in 2040: Population-Based Global Epidemiological Profiling","volume":"9","author":"Zhang","year":"2023","journal-title":"JMIR Public Health Surveill"},{"issue":"8","key":"10.1016\/j.ctrv.2024.102772_b0020","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/S1470-2045(23)00265-6","article-title":"Dysphagia-optimised intensity-modulated radiotherapy versus standard intensity-modulated radiotherapy in patients with head and neck cancer (DARS): a phase 3, multicentre, randomised, controlled trial","volume":"24","author":"Nutting","year":"2023","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2024.102772_b0025","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1002\/hed.26100","article-title":"Transoral robotic surgery for recurrent cancers of the upper aerodigestive tract-Systematic review and meta-analysis","volume":"42","author":"Hardman","year":"2020","journal-title":"Head Neck"},{"key":"10.1016\/j.ctrv.2024.102772_b0030","unstructured":"Cancer Facts & Figures 2023 [Internet]. Cancer.org. Accessed December 26,2023. Available from https:\/\/www.cancer.org\/research\/cancer-facts-statistics\/all-cancer-facts-figures\/2023-cancer-facts-figures.html."},{"key":"10.1016\/j.ctrv.2024.102772_b0035","unstructured":"SEER*Explorer [Internet] Cancer.gov. Accessed December 26, 2023. Available from: https:\/\/seer.cancer.gov\/statistics-network\/explorer\/application.html."},{"key":"10.1016\/j.ctrv.2024.102772_b0040","unstructured":"Cancer statistics for the UK [Internet]. Cancer Research UK. 2015 [cited 2024 Mar 16]. Available from: https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics-for-the-uk."},{"key":"10.1016\/j.ctrv.2024.102772_b0045","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.2147\/OTT.S188148","article-title":"Management of recurrent nasopharyngeal carcinoma: current perspectives","volume":"12","author":"Perri","year":"2019","journal-title":"OncoTargets Ther"},{"issue":"10212","key":"10.1016\/j.ctrv.2024.102772_b0050","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet Lond Engl"},{"issue":"20","key":"10.1016\/j.ctrv.2024.102772_b0055","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1001\/jama.2023.20181","article-title":"Toripalimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: The JUPITER-02 randomized clinical trial","volume":"330","author":"Mai","year":"2023","journal-title":"J Am Med Assoc"},{"issue":"8","key":"10.1016\/j.ctrv.2024.102772_b0060","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/S1470-2045(21)00302-8","article-title":"Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial","volume":"22","author":"Yang","year":"2021","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2024.102772_b0065","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.ccell.2023.04.014","article-title":"Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309)","volume":"41","author":"Yang","year":"2023","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.ctrv.2024.102772_b0070","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1200\/JCO.21.02508","article-title":"Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study","volume":"41","author":"Harrington","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102772_b0075","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.719650","article-title":"The Optimal Second-Line Systemic Treatment Model for Recurrent and\/or Metastatic Head and Neck Squamous Cell Carcinoma: A Bayesian Network Meta-Analysis","volume":"12","author":"Zhan","year":"2021","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.ctrv.2024.102772_b0080","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.annonc.2020.12.007","article-title":"Nasopharyngeal carcinoma: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2020","volume":"32","author":"Bossi","year":"2021","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102772_b0085","first-page":"1","article-title":"Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102772_b0090","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13045-021-01084-4","article-title":"Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies","volume":"14","author":"Tian","year":"2021","journal-title":"J Hematol OncolJ Hematol Oncol"},{"key":"10.1016\/j.ctrv.2024.102772_b0095","doi-asserted-by":"crossref","first-page":"e390094","DOI":"10.1200\/EDBK_390094","article-title":"Rise of Antibody-Drug Conjugates: The Present and Future","volume":"43","author":"Shastry","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"10396","key":"10.1016\/j.ctrv.2024.102772_b0100","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S0140-6736(23)00521-4","article-title":"T-cell-engaging bispecific antibodies in cancer","volume":"402","author":"Van De Donk","year":"2023","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.ctrv.2024.102772_b0105","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ctrv.2024.102772_b0110","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer | NEJM","volume":"380","author":"Von Minckwitz","year":"2019","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.ctrv.2024.102772_b0115","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer","volume":"386","author":"Cort\u00e9s","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102772_b0120","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102772_b0125","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.ctrv.2024.102772_b0130","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer |","volume":"384","author":"Bardia","year":"2021","journal-title":"NEJM"},{"issue":"12","key":"10.1016\/j.ctrv.2024.102772_b0135","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2024.102772_b0140","doi-asserted-by":"crossref","first-page":"S1557","DOI":"10.1016\/j.annonc.2023.10.347","article-title":"211MO EV-302\/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la\/mUC)","volume":"34","author":"Powles","year":"2023","journal-title":"Ann Oncol"},{"issue":"22","key":"10.1016\/j.ctrv.2024.102772_b0145","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1056\/NEJMoa2306441","article-title":"Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions","volume":"389","author":"Caicun","year":"2023","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.ctrv.2024.102772_b0150","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1056\/NEJMoa2307980","article-title":"Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer","volume":"389","author":"Ahn","year":"2023","journal-title":"N Engl J Med"},{"issue":"16_suppl","key":"10.1016\/j.ctrv.2024.102772_b0155","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.8502","article-title":"First-in-human dose-escalation trial of BI 764532, a delta-like ligand 3 (DLL3)\/CD3 IgG-like T-cell engager in patients (pts) with DLL3-positive (DLL3+) small-cell lung cancer (SCLC) and neuroendocrine carcinoma (NEC)","volume":"41","author":"Wermke","year":"2023","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.ctrv.2024.102772_b0160","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","article-title":"Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma","volume":"385","author":"Nathan","year":"2021","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.ctrv.2024.102772_b0165","doi-asserted-by":"crossref","first-page":"813","DOI":"10.21037\/atm.2020.04.07","article-title":"EGFR in head and neck squamous cell carcinoma: exploring possibilities of novel drug combinations","volume":"8","author":"Rehmani","year":"2020","journal-title":"Ann Transl Med"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102772_b0170","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s12935-019-0863-5","article-title":"The prognostic significance of PD-L1 and PD-1 expression in patients with nasopharyngeal carcinoma: a systematic review and meta-analysis","volume":"19","author":"Huang","year":"2019","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.ctrv.2024.102772_b0175","article-title":"The evolving landscape of PD-1\/PD-L1 pathway in head and neck cancer","volume":"11","author":"Wei","year":"2020","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.ctrv.2024.102772_b0180","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.ejca.2005.09.036","article-title":"Tumor-associated antigenic pattern in squamous cell carcinomas of the head and neck \u2013 Analysed by SEREX","volume":"49","author":"Heubeck","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2024.102772_b0185","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"21","key":"10.1016\/j.ctrv.2024.102772_b0190","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1001\/jama.2023.19793","article-title":"Reporting of factorial randomized trials: extension of the CONSORT 2010 statement","volume":"330","author":"Kahan","year":"2023","journal-title":"J Am Med Assoc"},{"issue":"2","key":"10.1016\/j.ctrv.2024.102772_b0195","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2024.102772_b0200","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejca.2017.10.017","article-title":"Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria","volume":"88","author":"Tazdait","year":"2018","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.ctrv.2024.102772_b0205","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2024.102772_b0210","unstructured":"Common terminology criteria for adverse events (CTCAE) [Internet]. Cancer.gov. [cited 2024 Mar 16]. Available from: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf."},{"key":"10.1016\/j.ctrv.2024.102772_b0215","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.ctrv.2024.102772_b0220","doi-asserted-by":"crossref","unstructured":"Bossi P, Minuti G, Bra\u00f1a I, et al. Efficacy and safety of MCLA-129, an anti-EGFR\/c-MET bispecific antibody, in head and neck squamous cell carcinoma (HNSCC). In: Proceedings of European Society of Medical Oncology Asia Congress 2023 Dec 1-3; Singapore (362P).","DOI":"10.1016\/j.annonc.2023.10.470"},{"key":"10.1016\/j.ctrv.2024.102772_b0225","doi-asserted-by":"crossref","unstructured":"Xue L, Han Y, Zhang A, Li X et al. Efficacy and Safety of a Novel Anti-EGFR ADC MRG003 in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck patients. In: Proceeding of the European Society of Medical Oncology; 2023 Oct 20-23, Madrid (939P).","DOI":"10.1016\/j.annonc.2023.09.2083"},{"key":"10.1016\/j.ctrv.2024.102772_b0230","doi-asserted-by":"crossref","unstructured":"Xue L, Yang K, Fang M, et al. Results from two phase Il studies of SI-B001, an EGFR\u00d7HER3 bispecific antibody with\/without chemotherapy in patients (pts) with recurrent and metastatic headand neck squamous cell carcinoma (HNSCC). In: Proceedings of American Society of Clinical Oncology Congress; 2023 June 2-6 Chicago (6037).","DOI":"10.1200\/JCO.2023.41.16_suppl.6037"},{"key":"10.1016\/j.ctrv.2024.102772_b0235","unstructured":"Han F, Wang F, Shi Y et al. An Open-label, Multicenter Phase II Study to Evaluate the Efficacy and Safety of MRG003 in Patients with Recurrent\/Metastatic Nasopharyngeal Carcinoma. In: Proceedings of European Society of Medical Oncology Congress, 2023 Oct 20-24 Madrid (860MO)."},{"issue":"Suppl 2","key":"10.1016\/j.ctrv.2024.102772_b0240","first-page":"A466","article-title":"436 A phase II study of AK104, a bispecific antibody targeting PD-1 and CTLA-4, in patients with metastatic nasopharyngeal carcinoma (NPC) who had progressed after two or more lines of chemotherapy","volume":"9","author":"Mai","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ctrv.2024.102772_b0245","doi-asserted-by":"crossref","unstructured":"Doi T, Patel MR, Falchook GS, et al. DS-7300 (B7-H3 DXd Antibody Drug Conjugate [ADC]) Shows Durable Antitumor Activity in Advanced Solid Tumors: Extended Follow-up of a Phase 1\/2 Study. In: Proceedings of European Society of Medical Oncology Congress; 2022 Sept 9-13 Paris (4043).","DOI":"10.1016\/j.annonc.2022.07.582"},{"key":"10.1016\/j.ctrv.2024.102772_b0250","doi-asserted-by":"crossref","unstructured":"Michel L, Jimeno A, Sukari A, et al. Sacituzumab govitecan in patients with relapsed\/refractory advanced head and neck squamous cell carcinoma. In: Proceedings of European Society of Medical Oncology Congress; 2023 Oct 20-24 Madrid (859MO).","DOI":"10.1016\/j.annonc.2023.09.2005"},{"issue":"16_suppl","key":"10.1016\/j.ctrv.2024.102772_b0255","article-title":"BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic solid tumor: Results from a first-in-human phase 1 study","volume":"41","author":"Zhang","year":"2023","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2024.102772_b0260","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1002\/cncr.31304","article-title":"Efficacy and safety results of depatuxizumab mafodotin (ABT-414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor","volume":"124","author":"Goss","year":"2018","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.ctrv.2024.102772_b0265","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1007\/s10637-020-00908-3","article-title":"A phase 1 study evaluating safety and pharmacokinetics of losatuxizumab vedotin (ABBV-221), an anti-EGFR antibody-drug conjugate carrying monomethyl auristatin E, in patients with solid tumors likely to overexpress EGFR","volume":"38","author":"Cleary","year":"2020","journal-title":"Invest New Drugs"},{"issue":"7","key":"10.1016\/j.ctrv.2024.102772_b0270","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1001\/jamaoncol.2022.0503","article-title":"Evaluation of safety of treatment with anti-epidermal growth factor receptor antibody drug conjugate MRG003 in patients with advanced solid tumors: A phase 1 nonrandomized clinical trial","volume":"8","author":"Qiu","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ctrv.2024.102772_b0275","doi-asserted-by":"crossref","unstructured":"Swiecicki P, Yilmaz E, Rosenberg A et al. Enfortumab vedotin in the previously treated advanced Head and Neck Cancer Cohort of EV-202. In: Proceeding of American Society of Clinical Oncology Congress, 2023 June 2-6 Chicago (6017).","DOI":"10.1200\/JCO.2023.41.16_suppl.6017"},{"key":"10.1016\/j.ctrv.2024.102772_b0280","doi-asserted-by":"crossref","unstructured":"Hollebecque A, Lopez J, Sarina A et al. SGN-B6A, An Integrin Beta-6 Targeted Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors: Updated Results From a Phase 1 Study (SGNB6A-001). In: Proceedings of American Society of Clinical Oncology Congress; 2023 June 2-6 Chicago (3024).","DOI":"10.1200\/JCO.2023.41.16_suppl.3024"},{"issue":"16","key":"10.1016\/j.ctrv.2024.102772_b0285","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.1158\/1078-0432.CCR-21-0194","article-title":"Phase I, first-in-human study of the probody therapeutic CX-2029 in adults with advanced solid tumor malignancies","volume":"27","author":"Johnson","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2024.102772_b0290","series-title":"Proceedings of the American Society of Clinical Oncology Virtual Meeting, May 29-31, 2020","first-page":"526","article-title":"CX-2009, a CD166-directed PROBODY drug conjugate (PDC): results from the first-in-human study in patients with advanced cancer including breast cancer","author":"Boni","year":"2020"},{"issue":"4","key":"10.1016\/j.ctrv.2024.102772_b0295","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1158\/1535-7163.MCT-21-0652","article-title":"A first-in-human, phase I, multicenter, open-label, dose-escalation study of PCA062: An antibody-drug conjugate targeting P-cadherin, in patients with solid tumors","volume":"21","author":"Duca","year":"2022","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"10.1016\/j.ctrv.2024.102772_b0300","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s00280-018-3623-7","article-title":"A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer","volume":"82","author":"Patnaik","year":"2018","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"10.1016\/j.ctrv.2024.102772_b0305","first-page":"e193","article-title":"Clinical activity of MCLA-158 (petosemtamab), an IgG1 bispecific antibody targeting EGFR and LGR5, in advanced head and neck squamous cell carcinoma (HNSCC)","volume":"24","author":"Cohen","year":"2023","journal-title":"Lancet Oncol [Internet]"},{"key":"10.1016\/j.ctrv.2024.102772_b0310","doi-asserted-by":"crossref","unstructured":"Melero I, Grande E, de Miguel MJ, et al. Safety and Preliminary Efficacy of GEN1042 (DuoBody\u00ae-CD40x4-1BB) Combination Therapy in Patients With Advanced Solid Tumors. In: Proceedings of European Society of Medical Oncology Immuno-Oncology Congress; 2022 Dec 7-9 Geneva (Poster 175P).","DOI":"10.1016\/j.iotech.2022.100287"},{"key":"10.1016\/j.ctrv.2024.102772_b0315","doi-asserted-by":"crossref","unstructured":"Akce M, Hu-Lieskovan S, Reilley M, et al. A Phase 1 multiple-ascending dose study to evaluate the safety and tolerability of XmAb23104 (PD-1 x ICOS) in subjects with selected advanced solid tumors (DUET-3). In: Proceedings of American Society of Clinical Oncology Congress; 2022 Jun 3-7 Chicago (2604).","DOI":"10.1200\/JCO.2022.40.16_suppl.2604"},{"issue":"5","key":"10.1016\/j.ctrv.2024.102772_b0320","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1158\/1078-0432.CCR-22-1449","article-title":"A phase 1 First-in-human study of FS118, a tetravalent bispecific antibody targeting LAG-3 and PD-L1 in patients with advanced cancer and PD-L1 resistance","volume":"29","author":"Yap","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.ctrv.2024.102772_b0325","doi-asserted-by":"crossref","first-page":"e006654","DOI":"10.1136\/jitc-2022-006654","article-title":"Phase I trial of KN046, a novel bispecific antibody targeting PD-L1 and CTLA-4 in patients with advanced solid tumors","volume":"11","author":"Ma","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"6","key":"10.1016\/j.ctrv.2024.102772_b0330","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100309","article-title":"Pan-Asian adaptation of the EHNS\u2013ESMO\u2013ESTRO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with squamous cell carcinoma of the head and neck","volume":"6","author":"Keam","year":"2021","journal-title":"ESMO Open"},{"issue":"12","key":"10.1016\/j.ctrv.2024.102772_b0335","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.1002\/cam4.3953","article-title":"Cetuximab combined with paclitaxel or paclitaxel alone for patients with recurrent or metastatic head and neck squamous cell carcinoma progressing after EXTREME","volume":"10","author":"Chevalier","year":"2021","journal-title":"Cancer Med"},{"issue":"19","key":"10.1016\/j.ctrv.2024.102772_b0340","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.ctrv.2024.102772_b0345","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1200\/JCO.2016.70.1524","article-title":"Pembrolizumab for Platinum- and cetuximab-refractory head and neck cancer: results from a single-arm, Phase II Study","volume":"35","author":"Bauml","year":"2017","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.ctrv.2024.102772_b0350","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.6018","article-title":"Results of a phase II randomized controlled clinical trial comparing efficacy of cabazitaxel versus docetaxel as second-line or above therapy in recurrent head and neck cancer","volume":"35","author":"Joshi","year":"2017","journal-title":"J Clin Oncol"},{"issue":"14_suppl","key":"10.1016\/j.ctrv.2024.102772_b0355","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2004.22.90140.5502","article-title":"Cetuximab monotherapy is active in patients (pts) with platinum-refractory recurrent\/metastatic squamous cell carcinoma of the head and neck (SCCHN): Results of a phase II study","volume":"22","author":"Trigo","year":"2004","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ctrv.2024.102772_b0360","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1093\/annonc\/mdz388","article-title":"Afatinib versus methotrexate as second-line treatment in Asian patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 3): an open-label, randomised phase III trial","volume":"30","author":"Guo","year":"2019","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2024.102772_b0365","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1007\/s11864-023-01101-3","article-title":"Recurrent\/metastatic nasopharyngeal carcinoma treatment from present to future: where are we and where are we heading?","volume":"24","author":"Juarez-Vignon Whaley","year":"2023","journal-title":"Curr Treat Options Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2024.102772_b0370","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.annonc.2022.12.007","article-title":"Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial","volume":"34","author":"Chan","year":"2023","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.ctrv.2024.102772_b0375","first-page":"1281","article-title":"Tubulin inhibitor-based antibody-drug conjugates for cancer therapy","volume":"22","author":"Chen","year":"2017","journal-title":"Mol J Synth Chem Nat Prod Chem"},{"key":"10.1016\/j.ctrv.2024.102772_b0380","first-page":"1024239","article-title":"Response of patients with taxane-refractory advanced urothelial cancer to enfortumab vedotin, a microtubule-disrupting agent","volume":"2023","author":"Miyake","year":"2023","journal-title":"Case Rep Urol"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102772_b0385","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1038\/s41467-023-38407-7","article-title":"Clinical efficacy and biomarker analysis of dual PD-1\/CTLA-4 blockade in recurrent\/metastatic EBV-associated nasopharyngeal carcinoma","volume":"14","author":"Lim","year":"2023","journal-title":"Nat Commun"},{"issue":"36","key":"10.1016\/j.ctrv.2024.102772_b0390","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.1200\/JCO.2017.73.3675","article-title":"Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1\u2013positive nasopharyngeal carcinoma: results of the KEYNOTE-028 study","volume":"35","author":"Hsu","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102772_b0395","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.617184","article-title":"The impact of comorbidity on survival in patients with head and neck squamous cell carcinoma: A nationwide case-control study spanning 35 years","volume":"10","author":"Ruud Kj\u00e6r","year":"2021","journal-title":"Front Oncol"},{"issue":"8","key":"10.1016\/j.ctrv.2024.102772_b0400","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41571-023-00783-w","article-title":"Optimizing the safety of antibody\u2013drug conjugates for patients with solid tumours","volume":"20","author":"Tarantino","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"13","key":"10.1016\/j.ctrv.2024.102772_b0405","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.3390\/cancers13133126","article-title":"Therapeutic potential of antibody-drug conjugate-based therapy in head and neck cancer: A systematic review","volume":"13","author":"Perrotti","year":"2021","journal-title":"Cancers"},{"issue":"16","key":"10.1016\/j.ctrv.2024.102772_b0410","doi-asserted-by":"crossref","first-page":"4361","DOI":"10.1039\/C8CS00676H","article-title":"Cleavable linkers in antibody\u2013drug conjugates","volume":"48","author":"Bargh","year":"2019","journal-title":"Chem Soc Rev"},{"key":"10.1016\/j.ctrv.2024.102772_b0415","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.103960","article-title":"Incidence of antibody\u2013drug conjugates-related pneumonitis in patients with solid tumors: A systematic review and meta-analysis","volume":"184","author":"Zhu","year":"2023","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102772_b0420","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40164-021-00250-1","article-title":"Recent advances and challenges of bispecific antibodies in solid tumors","volume":"10","author":"Wu","year":"2021","journal-title":"Exp Hematol Oncol"},{"issue":"11","key":"10.1016\/j.ctrv.2024.102772_b0425","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","article-title":"Platinum-based chemotherapy plus cetuximab in head and neck cancer","volume":"359","author":"Vermorken","year":"2008","journal-title":"N Engl J Med"},{"issue":"16_suppl","key":"10.1016\/j.ctrv.2024.102772_b0430","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.6013","article-title":"A phase 1 dose-escalation and expansion study of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, given as monotherapy and in combination with pembrolizumab in patients with recurrent\/metastatic HPV16+ head and neck cancer","volume":"41","author":"Chung","year":"2023","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.ctrv.2024.102772_b0435","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.6005","article-title":"Dose expansion results of the bifunctional EGFR\/TGF\u03b2 inhibitor BCA101 with pembrolizumab in patients with recurrent, metastatic head and neck squamous cell carcinoma","volume":"41","author":"Hanna","year":"2023","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.ctrv.2024.102772_b0440","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.6020","article-title":"Long-term follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF-\u03b2 and PD-L1, in advanced squamous cell carcinoma of the head and neck (SCCHN)","volume":"39","author":"Cho","year":"2021","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2024.102772_b0445","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMoa053422","article-title":"Radiotherapy plus Cetuximab for squamous-cell carcinoma of the head and neck","volume":"354","author":"Bonner","year":"2006","journal-title":"N Engl J Med"},{"issue":"15_suppl","key":"10.1016\/j.ctrv.2024.102772_b0450","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS6091","article-title":"TrilynX: A phase 3 trial of xevinapant and concurrent chemoradiation for locally advanced head and neck cancer","volume":"39","author":"Bourhis","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102772_b0455","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1200\/EDBK_349411","article-title":"Neoadjuvant immunotherapy: leveraging the immune system to treat early-stage disease","volume":"42","author":"Mittendorf","year":"2022","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.ctrv.2024.102772_b0460","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1125905","article-title":"Mechanistic rationales for combining immunotherapy with radiotherapy","volume":"14","author":"Chi","year":"2023","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.ctrv.2024.102772_b0465","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1158\/2159-8290.CD-20-1445","article-title":"Design and efficacy of a monovalent bispecific PD-1\/CTLA4 antibody that enhances CTLA4 blockade on PD-1+ activated T cells","volume":"11","author":"Dovedi","year":"2021","journal-title":"Cancer Discov"},{"issue":"10","key":"10.1016\/j.ctrv.2024.102772_b0470","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.medj.2023.07.006","article-title":"A pan-cancer clinical platform to predict immunotherapy outcomes and prioritize immuno-oncology combinations in early-phase trials","volume":"4","author":"Hernando-Calvo","year":"2023","journal-title":"Med"},{"key":"10.1016\/j.ctrv.2024.102772_b0475","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104265","article-title":"UGT1A1 Testing in Breast Cancer: should it become routine practice in patients treated with antibody-drug conjugates?","volume":"196","author":"Ibrahim","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ctrv.2024.102772_b0480","first-page":"zxae050","article-title":"Pharmacist perspectives on emerging T cell\u2013engaging bispecific therapies in cancer therapeutics","author":"Moore","year":"2024","journal-title":"Am J Health Syst Pharm"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737224001002?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737224001002?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T15:57:56Z","timestamp":1729094276000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737224001002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":96,"alternative-id":["S0305737224001002"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2024.102772","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A systematic review of antibody-drug conjugates and bispecific antibodies in head and neck squamous cell carcinoma and nasopharyngeal carcinoma: Charting the course of future therapies","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2024.102772","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102772"}}